Skip to main content

5 Result(s)

within English Remove this filter Neurosciences Remove this filter Judith Haas Remove this filter Article Remove this filter

and

  1. Article

    Open Access

    Long-term real-world effectiveness and safety of fingolimod over 5 years in Germany

    To evaluate the 5-year real-world benefit–risk profile of fingolimod in patients with relapsing–remitting MS (RRMS) in Germany.

    Tjalf Ziemssen, Michael Lang, Stephan Schmidt, Holger Albrecht… in Journal of Neurology (2022)

    Download PDF (1084 KB) View Article

  2. Article

    Open Access

    Clinical and Demographic Profile of Patients Receiving Fingolimod in Clinical Practice in Germany and the Benefit–Risk Profile of Fingolimod After 1 Year of Treatment: Initial Results From the Observational, Noninterventional Study PANGAEA

    The population with multiple sclerosis receiving treatment in clinical practice differs from that in randomized controlled trials (RCTs). An assessment of the real-world benefit–risk profile of therapies is ne...

    Tjalf Ziemssen, Michael Lang, Björn Tackenberg, Stephan Schmidt… in Neurotherapeutics (2018)

    Download PDF (554 KB) View Article

  3. No Access

    Article

    Symptomatology of MS: results from the German MS Registry

    Since 2002, an MS Registry has been implemented by the German MS Society in more than 100 German MS centres. The objective is to provide information about disease characteristics, and to monitor the health car...

    Kristin Stuke, Peter Flachenecker, Uwe K. Zettl, Wolfgang G. Elias… in Journal of Neurology (2009)

  4. No Access

    Article

    Current issues in immunomodulatory treatment of multiple sclerosis

    Dr. Martin Stangel, Ralf Gold, Achim Gass, Judith Haas, Stefan Jung… in Journal of Neurology (2006)

  5. No Access

    Article

    Mycophenolate-mofetil in the treatment of refractory multiple sclerosis

    Norbert Ahrens, Abdulgabar Salama, Judith Haas in Journal of Neurology (2001)